StreetAlpha.app
Home › Stocks › ADMA

Adma Biologics, Inc. (ADMA)

Healthcare
$13.17
▼ −1.27%
LAST CLOSE · NOV 20

ADMA Biologics makes immune globulin treatments from human blood plasma for patients with weakened immune systems. It last closed at $13.17 on Nov 20, down 1.27% on the day. The next earnings report for ADMA is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, ADMA reported EPS of $0.22 on revenue of $141.1M, with revenue up 5.1% from a year ago. Over its last 8 reports the stock moved an average of 10.3% the session after earnings. Over the last 12 months ADMA insiders bought $468K of stock on the open market and sold $3.4M, according to SEC Form 4 filings.

AI Auto Pilots
Is ADMA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ADMA.

Key Stats

Last 12 months
Results
Revenue
$519.2M
+6.3% vs a year ago
Net income
$182.4M
−12.9% vs a year ago
EPS (diluted)
$0.77
−10.5% vs a year ago
Free cash flow
$132.9M
25.6% margin
Valuation
Market cap
$2.9B
221.9M shares
P/E
17.1
Price over 12 month EPS
Price to sales
5.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$124.6M
At Sep 30
Debt
$195.9M
At Sep 30
Shareholder equity
$438.5M
Buybacks
$189.2M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $80.9M$80.9MFY2021FY2022: $154.1M$154.1MFY2022FY2023: $258.2M$258.2MFY2023FY2024: $426.5M$426.5MFY2024FY2025: $510.2M$510.2MFY2025

From ADMA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
$0.22
Quarter ended Sep 2026
Year ago EPS
$0.15
+46.7% on a GAAP basis
Revenue
$141.1M
+5.1% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.46Dec '24Mar 2025: $0.11Mar '25Jun 2025: $0.14Jun '25Sep 2025: $0.15Sep '25Dec 2025: $0.20Dec '25Mar 2026: $0.19Mar '26Jun 2026: $0.16Jun '26Sep 2026: $0.22Sep '26Latest $0.22
Revenue by quarter
Dec 2024: $117.5MDec '24Mar 2025: $114.8MMar '25Jun 2025: $122.0MJun '25Sep 2025: $134.2MSep '25Dec 2025: $139.2MDec '25Mar 2026: $114.5MMar '26Jun 2026: $124.4MJun '26Sep 2026: $141.1MSep '26Latest $141.1M
How ADMA moved after its last 8 reports
Average move the session after a report ±10.3%
Nov 4, 2026After the close+26.1%
Aug 5, 2026After the close+8.6%
May 6, 2026After the close−16.0%
Feb 25, 2026After the close−3.2%
Jan 12, 2026Time not announced−0.1%
Nov 5, 2025After the close−8.7%
Aug 6, 2025After the close−9.7%
May 7, 2025After the close−10.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ADMAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ADMA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ADMA

Technical Analysis

ADMA · as of the Nov 20 close · updated each morning
Uptrend, nearing overbought

The stock is 6% above its 20 day and 17% above its 50 day average. It is 19% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 62), near overbought. The nearest support is the Pivot S1 at $13.02, and the nearest resistance the Pivot at $13.25.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNear overbought
VolatilityHigh, 4.7%/day
Key levels
$20.4652 week high+55.4%
$13.77Swing high (Nov 5)+4.6%
$13.39Pivot R1+1.7%
$13.25Pivot+0.6%
$13.17Last close
$13.02Pivot S1−1.1%
$12.4020 day average−5.8%
$10.9750 day average−16.7%
$10.64200 day average−19.2%
$10.57Swing low (Oct 23)−19.7%
$10.10100 day average−23.3%
$7.2152 week low−45.3%
Indicators
RSI (14)62.14Strong, overbought above 70Neutral
MACD0.75Above its signal lineBullish
Stochastic78.7Middle of its rangeNeutral
ADX (14)37.0Trending up
Williams %R-26.1Oversold below −80, overbought above −20Neutral
CCI (20)57.4Oversold below −100, overbought above 100Neutral
Rate of change+3.5%Change over 10 sessionsBullish
ATR (14)$0.62Typical daily range, 4.7% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for ADMA

What happened before

See how ADMA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ADMA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ADMA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ADMAHow many large options trades hit ADMA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ADMA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●152 buying vs 153 selling
  • ▼Held by funds -2.1 pts
  • ▲Funds holding +7
  • ▼Superinvestors: 2 added, 4 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding330323+2.2%
In funds' top 10330.0%
Held by funds90.6%92.7%−2.1 pts
New / increased40 / 11248 / 90+10.1%
Reduced / sold out119 / 34148 / 87−34.9%
Put/call ratio0.530.48+9.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ADMA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ADMA Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$468K4 buys · 2 insiders
Sold$3.4M7 sales · 3 insiders
91% of the selling was under pre-arranged trading plans.
2025-12 sold $416K2026-02 sold $338K2026-03 bought $217K2026-03 sold $476K2026-05 bought $251K2026-11 sold $2.2MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 16Adam S GrossmanPresident and CEOSale plan21,000$13.72$288K
Nov 16Lawrence P. GuiheenDirectorSale10,000$13.92$139K
Nov 5Adam S GrossmanPresident and CEOSale plan147,000$12.00$1.8M
May 27Jerrold B GrossmanDirectorBuy6,400$7.91$51K
May 12Jerrold B GrossmanDirectorBuy12,500$8.01$100K
May 11Jerrold B GrossmanDirectorBuy12,500$8.01$100K
Every insider buy and sale for ADMA over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ADMA insider trades →

From SEC Form 4 filings by ADMA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ADMA is in one of them and how their past ADMA trades turned out.

ADMA in the AI portfolios
Loading…

ADMA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ADMA in an article yet. Here's the latest on the wider market.

ADMA in the news

About Adma Biologics

ADMA Biologics is a biopharmaceutical company based in Ramsey, New Jersey. It makes specialty biologics from human blood plasma for people with weakened immune systems and for people at risk of certain infectious diseases. Its main products are ASCENIV and BIVIGAM, two immune globulin treatments for primary immunodeficiency, and Nabi-HB, which is used after exposure to hepatitis B. The company also operates plasma collection centers, sells some plasma to other manufacturers, and its products are mainly used by physician specialists.

Headquarters
Ramsey, NJ